Fundacja Saltus (KRS 0000406467, NIP 5851463659) is a Polish company, headquartered in Sopot, Pomorskie voivodeship. Fundacja Saltus operates in: Research and experimental development on social sciences and humanities (PKD 72.20.Z). Industry: Research and development. The company has been listed in the National Court Register since December 28, 2011. Fundacja Saltus's most recently reported net revenue was 0 PLN for 2024.
No reported revenue
The company reported no revenue in any available reporting year. This may indicate a non-operating entity.
No arrears identified in the analysed sources
No arrears or bankruptcy proceedings identified in the analysed sources.
Business profile - Fundacja Saltus
Identity
- Name
- Fundacja Saltus
- Legal form
- FUNDACJA
- Founded
- December 28, 2011
- Registry status as of
- June 24, 2026
- Latest entry
- June 24, 2026
- Founding act
- 19.12.2011 R.
Articles of association history (4)
- December 19, 2011: 19.12.2011 R.
- March 25, 2014: 25.03.2014R. ZMIENIONO PAR.7, PAR.8 I PAR.25 STATUTU
- July 17, 2014: 17.07.2014R. UCHWAŁA RADY FUNDATORÓW - ZMIANA PARAGRAFU 10 TRZECI TIRET
- 31 LIPCA 2025 R., ZMIANIE ULEGŁY NASTĘPUJĄCE PARAGRAFY: - PAR. 1 UST. 1 I UST.2, PAR. 7, PAR. 8, PAR. 10, PAR. 11, PAR. 14, PAR. 16, PAR. 18, PAR. 20, PAR. 27 UST. 3 USUNIĘCIE PARAGRAFÓW 25 I 26.
Activities
Other activities
General codes (divisions and groups)
General codes indicate a PKD division or group without a specific subclass.
Address and contact
- Address
- WŁADYSŁAWA IV, 22, 81-743, SOPOT, POLSKA
- Voivodeship
- POMORSKIE
- District
- M. SOPOT
- Not disclosed in the registry
- Website
- Not disclosed in the registry
- E-delivery address
- AE:PL-60156-49753-WFVIV-22
Risk and payment profile - Fundacja Saltus
Credibility rating
47.1 / 100
Average credibility
Insolvency risk
Very low
Elevated threat
Closure risk
38
/ 100
Risk comparison - scale 0 (safe) → 100 (critical)
Organisational stability signals
No instability signals - ownership, management, PKD codes and company name remain relatively stable.
Shareholder changes
0
0/14 yrs
Board changes
1
1/14 yrs
PKD changes
2
2/14 yrs
Name changes
1
1/14 yrs
Data from 14 years of registry activity.
Credibility history
Payment reliability score from 2018–2024
Current: D (47/100)
Trend: deteriorating (-2.8 pts/year)
Słaba wiarygodność płatnicza – wskaźniki finansowe sugerują podwyższone ryzyko opóźnień lub niewykonania zobowiązań.
Trade credit limit history
Standard limit from 2018–2024
Current: 44.5 K PLN
Safe: 13.3 K PLN
Difference between risk models
Closure - probability of ceasing operations (operational continuity). Insolvency - probability of formal bankruptcy / restructuring. The models use different data - results can diverge significantly when balance-sheet data is incomplete.
Operational status - Fundacja Saltus
Founded
December 28, 2011
14 years in operation
Legal form
FUNDACJA
Registry: RejP
Headquarters
SOPOT
POMORSKIE
Primary PKD
72.20.Z
Research and experimental development on social sciences and humani…
Board
1 person
Sup. board: 3
Filed years
7 years
2018–2024 · profitable: 0/7
Registry entries
32
latest: June 24, 2026
Risk signals
Revenue
0 PLN
2024
Net profit
-491.2 K PLN
2024
Assets
748.0 K PLN
2024
Equity
725.4 K PLN
2024
EBITDA
N/A
2024
no depreciation data
Valuation
426.9 K PLN
Low confidence
Low confidence
Companies in the same location
Public procurement
Trademarks
Reviews
Rate business credibility - Fundacja Saltus.
No ratings
Related articles
News
Bioceltix in the final EMA dialogue phase: BCX-CM-J could become Europe's first veterinary cell-therapy drug for dogs
Wrocław-based Bioceltix S.A. (KRS 0000744521) entered Q2 2026 in the final EMA dialogue phase on BCX-CM-J – potentially Europe's first veterinary cell-therapy drug based on mesenchymal stem cells, for dogs with osteoarthritis. Responses to the EMA's final questions are due in May 2026; a CVMP recommendation and marketing authorisation are possible in Q3/Q4 2026. A pre-commercial biotech: it closed 2024 with a PLN 14.9m loss on zero revenue and PLN 33.6m of cash at year-end. Trigon DM maintains a buy rating with a PLN 127.2 price target.
News
Captor Therapeutics: PLN 36m of cash at 30 September 2025, runway to mid-2026 – clinical data versus the cash clock
Wrocław-based Captor Therapeutics S.A. (KRS 0000756383) – a pre-commercial biotech specialising in targeted protein degradation (TPD) – closed Q3 2025 with PLN 36m of cash and grants securing funding to mid-2026. CT-01 (hepatocellular carcinoma) entered Phase I, with the first patient dosed at the Barcelona Clinic Liver Cancer. CT-03, an MCL-1 degrader, is close to clinical entry. Without a new R&D partnership or share issue in 2026, the company will need additional financing.
